[Federal Register Volume 75, Number 136 (Friday, July 16, 2010)]
[Notices]
[Page 41501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-17430]



[[Page 41501]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

A Transgenic Model of Human Basal Triple Negative Breast Cancer [C3(l)-
tag mice]

    Description of Invention: Basal triple-negative breast cancer 
(TNBC) is a common form of human breast cancer for which there are no 
specific, targeted therapies, unlike hormone-responsive or Her2+ breast 
cancers. TNBC has a much worse prognosis than hormone receptor + cancer 
and is disproportionately high in the African-American population. NIH 
scientists have created and characterized a transgenic model that is 
currently an excellent mouse model for TNBC that shares important 
molecular characteristics of human TNBC, making it highly useful for 
preclinical testing of drugs and novel therapies. This model may 
provide a valuable means of identifying new drugs and therapies that 
could be translated to human clinical trials. The mouse model also 
develops prostate intraepithelial neoplasia and prostate cancer, 
therefore has also been used for studies of prostate cancer. The 
studies using the mouse model may fill important public health service 
needs.
    Inventor: Jeffrey E. Green (NCI).
    Patent Status: HHS Reference No. E-191-2010/0--Research Tool. 
Patent protection is not being pursued for this technology.
    Licensing Status: Available for licensing under a Biological 
Materials License Agreement.
    Licensing Contact: Betty Tong, Ph.D.; 301-594-6565; 
[email protected].
    Collaborative Research Opportunity: The Transgenic Oncogenesis and 
Genomics Section of the Laboratory of Cancer Biology and Genetics, 
Center for Cancer Research, is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this mouse model of TNBC to study 
cancer biology and for preclinical testing. Please contact John Hewes, 
Ph.D. at 301-435-3121 or [email protected] for more information.

Improved Pepper Spray for Repellency and Incapacitation

    Description of Invention: Non-lethal means of temporarily 
incapacitating a person are greatly needed for law enforcement and for 
personal protection. A common approach is to use pepper spray. Although 
current pepper sprays are effective, they cause pain for excessively 
long periods, and could be life threatening for people who suffer from 
asthma and have hypersensitive airways. This technology describes a 
composition for use in an aerosol or spray, that when administered, 
causes a painful stimulation and incapacitates a person for only a 
brief period. This technology may improve safety over currently 
available pepper sprays.
    Application: Incapacitating pepper spray with reduced toxicity.
    Development Status: Early stage.
    Inventors: Peter M. Blumberg and Larry V. Pearce (NCI).
    Patent Status: U.S. Provisional Application No. 61/340,063 filed 12 
Mar 2010 (HHS Reference No. E-048-2010/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Charlene Sydnor, Ph.D.; 301-435-4689; 
[email protected].

    Dated: July 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-17430 Filed 7-15-10; 8:45 am]
BILLING CODE 4140-01-P